Archive for the ‘Proteomics’ Category
KINAXO’s Cellular Target Profiling® reveals mTOR as a new target of Celebrex
Last Updated on Sunday, 10 May 2009 08:46 Written by admin Sunday, 10 May 2009 08:46
Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis and acute pain. In addition, celecoxib’s anti-proliferative effect has earned it a place in numerous clinical trials against several malignancies.
The discovery that celecoxib targets mTOR contributes to a better understanding of the drug’s mode of action and efficacy in cancer patients. mTOR (mammalian target of rapamycin) acts as a central regulator of cell proliferation, cell survival, angiogenesis and cell metabolism. Moreover, mTOR is a key intracellular convergence point for a number of signaling pathways that are abnormally activated in many types of cancer.
As traditional drug development approaches become more and more expensive, drug repositioning has been widely recognized as an opportunity to expand a drug’s therapeutical applications. Here, Cellular Target Profiling® provides a powerful approach to revealing new targets that indicate additional or alternative medical uses for clinically validated or approved drugs. Further information on celecoxib reprofiling (AN3) and similar studies with other small molecules (e.g. profiling of the natural product geldanamycin, AN2) can be downloaded from our website at www.kinaxo.com.
Link to the news release
http://www.b3cnewswire.com/popup.php?id=149
About KINAXO
Kinaxo Biotechnologies GmbH is a privately-held biotechnology company based in Munich/Martinsried, Germany. We offer advanced chemical proteomics and phosphoproteomics services to support lead compound selection, target deconvolution, drug reprofiling, and off-target toxicity assessment. Kinaxo has several ongoing collaborations, including with Boehringer Ingelheim, Johnson & Johnson and Takeda.
Posted under Cancer Research, Drug Development, Europe, Medicinal Chemistry, Press Releases, Proteomics, Targeted Libraries | No Comments
Molecular Fingerprints Point The Way To Earlier Cancer Diagnosis And More Targeted Treatment
Last Updated on Friday, 27 March 2009 09:52 Written by admin Friday, 27 March 2009 09:52
ScienceDaily (Mar. 27, 2009) — Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer.
You’ve likely heard about metabolites; your physician probably screens for some known ones such as triglycerides or cholesterol at your annual physical. Scientists suspect we have about 3,000 metabolites that come from our food or are synthesized from different compounds in our bodies.
Dr. Sreekumar, a cancer researcher at the Medical College of Georgia Cancer Center, wants those screens of the blood or urine to also detect early signs of cancers such as leukemia, bladder, kidney and breast when the chance for cure is best.
He’s already begun to identify metabolites that indicate not only the presence of prostate cancer, but its aggressiveness, a tool that could help tailor optimal treatment. The search began in men at risk: those with elevated prostate specific antigen, or PSA, levels. A PSA test along with a digital rectal exam is today’s standard for prostate screening so physicians typically do both in men age 50 and older. But PSA levels are actually better at helping determine if prostate cancer has returned, Dr. Sreekumar says.
Elevated levels of PSA, a protein, are not always predictive of cancer, which means a lot of men get unnecessary biopsies. PSA measurements also can’t distinguish between tumors that have a good outcome versus those with a poor one.
“The physician does not really have the tools in hand to really say that this tumor will spread to other organs or not.” says the Georgia Cancer Coalition Distinguished Cancer Scholar. “We want to find clinical markers that supplement PSA.”
Aggressiveness is a major factor in prostate cancer treatment. In fact some men with slow growing disease likely won’t even need treatment. So he wants to provide a complement of biomarkers that accurately diagnose and categorize the disease then help monitor success of treatment. These early studies indicate a urine test may one day be possible to do just that.
He and colleagues at the University of Michigan reported in the Feb. 12 issue of Nature what appears to be one of the first metabolites implicated in cancer invasion. They looked at 1,126 metabolites in 262 samples taken from men with high PSA levels. They consistently found elevated levels of the amino acid sarcosine in the prostate tissues of men with cancer; levels were highest in what appeared to be the most aggressive tumors.
Sarcosine, a modified form of the amino acid glycine, was a known entity but its function was unclear. Scientists thought it might be a dumping ground for excess methyl groups needed to enable chemical changes of genes, proteins and other body components that can affect what and how much they do.
This process called methylation can be a good thing – like when it’s helping an embryo develop – but when it goes badly, it can cause disease such as cancer. While sarcosine’s dumping role seemed to protect from cancer, the Michigan scientists found its action actually helps induce tumors. In fact, when they added it to prostate cancer cells, the cells became more aggressive. Exactly how that process works is still under study but the findings were pretty consistent.
“When we looked at patients with metastatic disease, sarcosine levels were sky high compared to patients with localized tumors,” says Dr. Sreekumar. “It’s enabling invasion.”
Because cancer and people are both very heterogenous, measures need to be taken in larger population samples, he says. Also, they found a small group of patients with negative biopsies and high sarcosine levels. “We don’t know how many of them have missed cancer,” says Dr. Sreekumar who joined the MCG faculty in February.
These are among the reasons he believes in strength in numbers. “In the real world of biomarkers, you want 100 percent sensitivity. If the patient has cancer, you want to pick it up. We need to have a kind of multiplex test where you can test for say10 different entities and have a greater confidence that what you are stating about the tumor is true. Our goal is to develop such a panel and research on sarcosine is a first step toward achieving this.”
In his new position at MCG, he’s looking to expand the number of metabolites known to be predictive of prostate and other cancers. In prostate cancer, he’s beginning with follow up on other metabolites identified in the Michigan study in which researchers identified a total of six metabolites, including sarcosine, linked to increased tumor progression. A total of 89 metabolites were different in metastatic prostate cancer compared to localized disease.
He’s excited about what metabolites will one day tell cancer physicians and patients but adds that they are just a piece of what our bodies can tell us about a potential cancer growing inside. Scientists also need to continue to look at genes expressed by tumors and the proteins expressed by those genes to get the bigger picture. “It’s basically a systems approach you need to take,” he says.
The young scientist has worked with all those pieces in his relatively short career. He started his postdoctoral fellowship at the University of Michigan in1999, when the ability to look at gene expression was new. With his mentor, Dr. Arul M. Chinnaiyan, director of Michigan Center for Translational Pathology, Pathology Research Informatics and Cancer Bioinformatics at Michigan, he helped develop the next step: the ability to look at expression of hundreds of proteins at a time, instead of a handful, an important advance in light of the fact that there are about 1 million proteins. Recently they were among the first to venture into the world of metabolites, which are made by proteins.
“Previous technology was looking at a cell from a narrow perspective and cells never act in isolation, proteins never act in isolation, they always form complexes, act in pathways,” Dr. Sreekumar says.
His inspiration to follow those pathways is a fellow Ph.D. student who died too young and quickly of an aggressive leukemia and the fact that cancer is a leading cause of death worldwide.
Posted under Cancer Research, ChemInformatics, North America, Proteomics | No Comments
AnaSpec Introduces New SensoLyteTM MMP ELISA Kits
Last Updated on Thursday, 23 October 2008 02:46 Written by admin Thursday, 23 October 2008 02:46
San Jose, CA October 16, 2008
Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases involved in both normal and diseased tissue remodeling. They are capable of degrading all kinds of extracellular matrix (ECM) proteins, but also can process a number of bioactive molecules. MMPs are key players in normal and pathological processes, including embryogenesis, wound healing, inflammation, arthritis, and cancer.
MMPs share common structural and functional elements and are products of different genes. The three common domains include the pro-peptide, the catalytic domain and the haemopexin-like C-terminal domain linked to the catalytic domain by a flexible hinge region. MMPs are initially synthesized as inactive (latent) zymogens with a pro-peptide domain that must be removed before the enzyme is active.
AnaSpec is pleased to complement its MMP product line with a suite of SensoLyteTM MMP ELISA Kits. These kits are ideal for quantitative detection of MMP proteins (latent and active forms) in serum, plasma, cell culture supernates and urine. The SensoLyteTM ELISA Kits use a convenient, 96-well plate based format with colorimetric read-out.
AnaSpec?s widely used fluorescent SensoLyteTM MMP Activity Assays measure active MMPs in a convenient, 96-well plate-based method with highly sensitive fluorimetric read-out. A colorimetric read-out MMP Activity Assay kit is also available.
About AnaSpec
AnaSpec is a leading provider of integrated proteomics solutions to the world?s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.
For more information visit www.anaspec.com
Posted under New Products, North America, Peptide Research, Press Releases, Proteomics | No Comments
Thermo Fisher Scientific Holds European Proteomics Seminar Series on Protein Quantitation
Last Updated on Wednesday, 15 October 2008 10:51 Written by admin Wednesday, 15 October 2008 10:51
SAN JOSE, Calif. (October 15, 2008) – Thermo Fisher Scientific Inc., the
world leader in serving science, today announced the dates for its 2008
European Proteomics Seminar Series. The series, which takes place throughout
October and November, has become an established venue for scientific and
technological discussion and the sharing of practical tips.
The theme of the 2008 seminar series is protein quantitation. The seminars
will provide attendees with a unique opportunity to get firsthand
information about protein quantitation methods such as SILAC, the use of
tandem mass tagging (TMT) labels for relative quantitation of proteins with
the Thermo Scientific LTQ Orbitrap and targeted peptide quantitation applied
to biomarker verification.
Each seminar brings together world-class researchers in the fields of
proteomics and metabolomics who will share their results and insights. A
highlight of the discussions is electron transfer dissociation (ETD), a new
technique broadly applicable to proteomics and now available on LTQ Orbitrap
systems. Complementary to metabolomics and proteomics approaches in the
context of systems biology, functional proteomics, phosphopeptide and other
PTM analysis, signaling networks and top-down intact protein analyses add to
the breadth of topics covered by the seminars. In addition, the company’s
application scientists will cover practical issues related to sample
preparation, method setup and data processing.
The following is a list of dates and locations for the Thermo Scientific
Proteomics Seminars:
.    Monday, October 6, Tours, France.
.    Tuesday, October 7, Utrecht, The Netherlands.
.    Wednesday, October 8, Copenhagen, Denmark.
.    Thursday, October 9, Stockholm, Sweden.
.    Wednesday, October 15, Manchester, United Kingdom.
.    Thursday, October 16, Dublin, Ireland.
.    Friday, October 17, London, United Kingdom.
.    Monday, October 20, Vienna, Austria.
.    Tuesday, October 21, Munich, Germany.
.    Wednesday, October 22, Basel, Switzerland.
.    Thursday, October 23, Berlin, Germany.
.    Monday, November 10, Madrid, Spain.
.    Wednesday, November 12, Barcelona, Spain.
.    Thursday, November 13, Milan, Italy.
For more information about the Thermo Scientific Proteomics Seminars 2008,
including the full agendas for each event as well as registration, visit the
seminar Web site.
Thermo Scientific is part of Thermo Fisher Scientific, the world leader in
serving science.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, enabling our customers to make the world healthier, cleaner and
safer. With annual revenues of $10 billion, we have more than 30,000
employees and serve over 350,000 customers within pharmaceutical and biotech
companies, hospitals and clinical diagnostic labs, universities, research
institutions and government agencies, as well as environmental and
industrial process control settings. Serving customers through two premier
brands, Thermo Scientific and Fisher Scientific, we help solve analytical
challenges from routine testing to complex research and discovery. Thermo
Scientific offers customers a complete range of high-end analytical
instruments as well as laboratory equipment, software, services, consumables
and reagents to enable integrated laboratory workflow solutions. Fisher
Scientific provides a complete portfolio of laboratory equipment, chemicals,
supplies and services used in healthcare, scientific research, safety and
education. Together, we offer the most convenient purchasing options to
customers and continuously advance our technologies to accelerate the pace
of scientific discovery, enhance value for customers and fuel growth for
shareholders and employees alike. Visit www.thermofisher.com.
Posted under Europe, Europe, North America, Press Releases, Proteomics | No Comments
Biological Drugs Spurring an Evolution in Injectable Drug Delivery
Last Updated on Thursday, 3 January 2008 07:48 Written by admin Thursday, 3 January 2008 07:48
(Amherst, NH) – The success of recombinant protein drugs such as Enbrel, Remicade, and Herceptin in treating refractory conditions is fueling the search for protein and peptide-based therapeutic agents in oncology, inflammation and a host of other disease classes. Led by the proliferation of antibody-based drug candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and – ultimately – pharmaceutical marketers.
Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.
Compliance with drug therapy and disease management protocols has been and is a primary concern within the healthcare and pharmaceutical industries. Efforts to enhance compliance are having a non-negligible effect on drug formulations and delivery decisions, and can be a significant factor in the prescribing decisions of most physicians. Compliance concerns have driven and continue to drive investment in new drug delivery technologies.
As patients live longer and are diagnosed with chronic and often debilitating ailments, the result will be a dramatic increase in self-administration of drug therapies in non-traditional settings for a number of conditions. This trend is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that new drug product success no longer only depends on the medication itself but also on achieving a patient-friendly form of application.
New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Reusable injectors designed to accept prefilled syringes or drug cartridges will improve ease-of-use and increase alternative device share of the growing self-injection market. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.
These findings are contained in a comprehensive report, Injectable Drug Delivery: Evolving Markets, Emerging Opportunities. More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
7th Annual Protein Kinases Congress 10-12 March 2008 in Crowne Plaza Berlin City Centre, Berlin, Germany
Last Updated on Sunday, 4 November 2007 09:41 Written by admin Sunday, 4 November 2007 09:41
Innovating kinase inhibitor development is the key to successful clinical development. At Informa Life Sciences 7th Annual Protein Kinases Congress hear the latest thinking and strategies towards creating a selective inhibitor. Learn about new targets, industry trends in structure-based drug design, clinical case-studies and discuss the issue of cardiotoxicity.
For more information visit: http://www.iir-events.com/IIR-Conf/page.aspx?id=9547
Posted under Clinical Trials, Europe, Press Releases, Proteomics, Targeted Libraries | No Comments
PepCon-2008 Shenzhen, China on April 22-24, 2008
Last Updated on Sunday, 4 November 2007 09:23 Written by admin Sunday, 4 November 2007 08:51
Advances in peptide and protein researches are occurring at an ever increasing pace, in a wide range of fields and scientific disciplines. At this exciting time, it is especially important to promote scientific and technological exchange and cooperation at the international level.
To establish of a new educational and networking platform for protein and peptide sciences for international academic and industrial institutions and professionals in the area, PepCon Committee has assembled an exciting scientific program, PepCon-2008, of local and international invited speakers, covering the areas of cutting edge peptide and protein researches. More than 500 participants are expected, including 300 scientists from academic, industrial and government research institutions, 100 best local and international academic and medical research institutions as well as 80 world-famous bio-pharmaceutical and instrumentation industries. The conference will be held in Shenzhen, China on April 22-24, 2008 and will take the form of lectures, workshops, round table conferences and posters around the theme of Peptide & Protein Technology: From Concept to Market .
Featuring Six Tracks:
—- Great Minds and Innovations —-
Track I: Human Proteome Technologies- Deciphering Genome with powerful tools of Proteomics
Session 1: Frontier of Emerging Human Proteome Technologies
Session 2: Breakthrough in Major Disease Proteomics and System Biology
Session 3: Bioinformatics and Structural Proteomics
Session 4: Industry-Sponsored Symposia on Proteomics
Session 5: Protein/Peptide Structure Activity and Interaction
Track II: Protein/Peptide Biomarker Discoveries- Essential Pathway to Seek Specific Solutions
Session 6: Biomarkers in Early Drug Development
Session 7: Biomarkers in Clinical Development
Session 8: Biomarkers for Molecular Diagnostics
Session 9: Biomarker Testing and Analysis Technologies Development
Track III: Protein /Peptide Drug Discovery – Build up New Product Pipeline for Severe Diseases
Session 10: From CADD to Booming Peptide Drug Development
Session 11: Peptide / Protein as Anti-Cancer Agents
Session 12: Peptide / Protein as Anti-Infective Drugs
Session 13: Proteins/Peptides for CNS Diseases
Session 14: Proteins/Peptides For Cardiovascular & Cerebrovascular Disease
Session 15: Peptide / Protein Drug Delivery Technology
—- Demand on Improving Productivities —-
Track IV: Solutions to Antibodies/Vaccines- Off-shore Operation Opportunities
Session 16: Protein and Peptide Vaccine Research and Development
Session 17: Outsourcing Antibody Development and Production
Session 18: Investment and Business Trends Driving Biotechnology
Track V: Bioprocesses for Industrial Proteins- Riding on the Third Wave
Session 19: Rising Industrial Biotechnology for Large Scale Manufacturing & Contract Outsourcing
Session 20: New Expression Systems: Cell Line & Cell Culture Engineering
Session 21: Accelerating Production of Commercialized Proteins and Enzymes
Part VI: Renaissance of Peptide Market-Cost-Effective for Success
Session 22: Increasing Efficiency of Peptide Synthesis and Manufacturing
Session 23: off-Shore Customized Preparation/Production for Cost-Effective Therapeutics Development
Session 24: Technology Transfer for Protein/Peptide
www.bitlifesciences.com/Pepcon2008/
Posted under Asia, Peptide Research, Press Releases, Proteomics | No Comments
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Last Updated on Thursday, 18 October 2007 01:11 Written by admin Thursday, 18 October 2007 01:11
NEWARK, Del., Oct. 2 /PRNewswire-FirstCall/ — Strategic Diagnostics Inc. — today announced the launch of a new internet based catalog of antibody reagents in support of oncology-based research and discovery. These high-quality reagents have all been manufactured utilizing SDI’s proprietary Genomic Antibody Technology(TM) and will carry the SEQer(TM) brand. The catalog is available at http://antibodies.sdix.com online.
The catalog has launched with an initial offering of over 200 affinity purified antibody reagents. The Company will supplement this with up to an additional 25 new reagents each week as it strives to become recognized as the fastest-growing site of high quality, leading edge reagents for cancer research.
“Standard antibody production technologies have not changed in more than 20 years,” commented Matthew H. Knight, the Company’s President and Chief Executive Officer. “The SEQer antibodies in this catalog represent a breakthrough in antibody production and deliver multiple high performance attributes that reduced time, effort and data variation in the laboratory. In addition, the process that produces these reagents is high throughput as evidenced by our initial commitment to add up to 25 new antibody reagents each week. As recognition of SEQer antibody performance grows, we intend to increase this rate.”
Mr. Knight continued, “The launch of the SEQer catalog is a direct response to market research highlighting how the Life Science industry and particularly proteomics research has been inhibited by to the lack of high quality antibody reagents. The National Cancer Institute convened the Proteomic Technologies Reagents Resource Workshop in December, 2005, to identify the cancer research community’s expressed needs for validated and well characterized affinity capture reagents, including antibodies, to advance proteomics research platforms for the prevention, early detection, treatment, and monitoring of cancer. Many of the available catalogs typically broker pre-made antibodies from multiple sources and fall well short of meeting the performance needs of today’s biomedical researchers. With the launch of the SEQer catalog, Strategic Diagnostics is taking the first step to address this research bottleneck and meet a surging demand. We expect to build the fastest-growing source of oncology-focused antibody reagents which represents a meaningful share of the highly fragmented, $800 million annual market for catalog reagents.”
Strategic Diagnostics’ Genomic Antibody Technology(TM) (GAT) platform
Genomic Antibody Technology(TM) is a proprietary technology developed by Strategic Diagnostics (SDI). This high throughput, sequence-based, in vivo production process creates high-quality poly- or monoclonal reagents used in the discovery of new diagnostic biomarkers, unraveling the underlying mechanisms of disease, and as the basis of potential monoclonal antibody therapeutics. These antibodies are produced in 76 days and early adopters have tracked a first-time success rate in excess of 80%. SDI’s proprietary protein analysis software selects the optimal sequence associated with the specific protein or protein region the researcher wants to target and/or avoid. GAT expresses protein in vivo, thus assuring that the antigen targets and fully engages the natural mammalian immune system. This enables the production of an antibody that reacts more often and with greater fidelity when compared to reagents produced through traditional methods.
The SEQer catalog of antibodies addresses a number of well-known challenges associated with currently available reagents. Specifically, deficiencies in the ability to replicate the three dimensional conformation of target proteins through synthetic immunogens have resulted in reagents that do not reliably recognize or differentiate their intended targets. This, in turn, limits reagent performance and creates a level of uncertainty regarding the data produced with traditionally produced reagents. The SEQer antibody is focused on addressing the loss of productivity in research and development endeavors.
“The performance of our SEQer antibodies has been demonstrated with our many private and public collaborators in numerous assays,” Mr. Knight said. “The programs have included significantly large screens for oncology markers and the ability to stain disease-associated proteins across thousands of clinical biopsy samples. More targeted studies have shown the ability to differentiate highly conserved proteins in cell sorting assays, the ability to react with traditionally elusive proteins of interest, and be directed through SDI’s design algorithms to target functional sites in monoclonal applications.”
SDI’s GAT-produced antibodies are significantly better than traditional protein/peptide-produced antibodies, as they are produced in vivo by the host animal’s natural immune system, and are therefore able to behave both chemically and mechanically as any naturally produced antibody would.
Oncology Focus
The SEQer oncology-focused portfolio is comprised of antibody tools that target proteins associated with cancer pathogenesis and progression, thereby succeeding in delivering usable data for more proteins and in more applications. SDI strategically focused on the area of oncology, as more than half of NIH-funded research and the majority of proteomic efforts are currently focused on cancer research.
“SDI is focused on the oncology segment of life science research and is committed to creating industry leading solutions for oncology research,” Mr. Knight added. “This initial offering is a powerful step in that direction. As we expand this catalog, it will become the premier site for new and important antibody reagents for cancer research.”
About Strategic Diagnostics, Inc.
Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable “return on investment” by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company’s established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.
This news release contains forward-looking statements reflecting SDI’s current expectations. When used in this press release, the words “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project” “plan” and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI’s public filings with the U.S. Securities and Exchange Commission.
Posted under Cancer Research, Genomics & Pharmacogenomics, North America, Press Releases, Proteomics, Reagents | No Comments
Proteomic profiling to assess genetically modified crop safety
Last Updated on Wednesday, 11 January 2006 09:26 Written by admin Wednesday, 11 January 2006 09:26
Wednesday, January 11, 2006
By Sirpa O. Kärenlampi and Satu J. Lehesranta
It is generally accepted that traditional food is safe for the majority of consumers. For the introduction of a new variant or cultivar developed from a traditional crop plant, maximum limits have been set in some cases, e.g., for potato and oilseed rape, to the content of known toxins.
The requirements are much more stringent if the crop is developed by using genetic engineering. Why is it so? In a majority of cases seen so far, a new gene, often derived from other plants or microbial species, has been introduced to a non-predetermined location in the plant genome. It is quite feasible to ask the question whether the new gene products are safe or not. Therefore, for all genetically modified crop plants, the safety of the newly introduced proteins needs to be demonstrated before the plants can be released into the market.
Another point of concern is the random integration of the new gene into the plant genome. Both the new gene itself and its site of integration may give rise to unintended adverse effects. For example, transgene integration might interrupt regulatory sequences or open reading frames leading to novel fusion proteins and, thereby, modify plant metabolism. These modifications could compromise the safety of the food crops by, for instance, leading to the production of new allergens or toxins. Having the gene and the integration site well characterised should provide a good basis for the safety assessment.
However, it is a common practice today to perform a large number of analyses, so-called targeted analyses, to demonstrate that the characteristics of the novel crop are comparable with those of the conventional counterpart, in addition to the intended alterations. Targeted analyses include key macronutrients, micronutrients, antinutrients, and toxins. In certain cases, toxicity studies on experimental animals are advised. And yet, the question about the unintended effects does not seem to be covered in a way that would escape all criticism.
Cellini et al. have considered transgene integration in the context of naturally occurring DNA recombination. It is well known that genetic variation is the cornerstone of plant breeding. Natural chromosomal recombination plays a central role in generating new variation. Non-homologous end joining, which is the predominant form of recombination in plants, rarely occurs without any sequence alterations, and usually gives rise to deletions of up to more than 1 kb and introduction of new filler DNA. Since the double-strand break repair system involved in recombination is more error-prone in plants than in other organisms, errors that change the original sequence occur at a very high frequency. The fact that gene-rich regions (and genes) are hotspots for recombination has facilitated the emergence of novel characteristics in crop plants.
Integration of exogenous DNA (transgene) occurs via the same mechanism as natural recombination. Several types of rearrangements are thus observed, both in transgene integration sites and in natural recombination sites. While this mechanism provides a selection of natural variation for breeders, it is also a source of unintended effects similar to that in genetically engineered crop plants.
In the light of variation generated by natural recombination and by the repertoire of conventional breeding technologies exploited for decades, the question is how much variation in the overall genetic makeup of a crop plant might be generated by the transfer and integration of a single gene, compared to the variation already existing. A related question is how probable are the unintended effects that extend beyond this variation.
To answer these and other questions, we made a comparative analysis of eight GM lines of potato, including vector-only lines without the target gene. The parent cultivar, Desirée, and a line that had undergone tissue culture only, were included as non-GM comparators. Nine of 730 proteins showed statistically significant differences among the GM lines and controls. No new proteins that would be unique to the individual GM lines were observed. The conclusion from this study, supported by the EU-funded GMOCARE project, was that there was no evidence for any major changes in protein patterns of the GM lines tested.
It can be argued that proteomics is not sensitive enough to find differences between potato lines or varieties. The European breeders have developed a large number of very different potato cultivars, many of them with genes introgressed from other Solanum species. Of that diversity, we analysed 32 non-GM potato genotypes, including 21 conventional cultivars, eight landraces, and three lines of S. phureja. From that study it was obvious that there is a great deal of variation in the protein patterns of the different potato genotypes: out of 1111 protein spots analyzed, 1077 differed significantly among two or more genotypes. The protein profile of the diploid species S. phureja could be clearly distinguished from the ones of the tetraploid S. tuberosum genotypes.
These studies indicated that the variation between the non-GM cultivars/genotypes was much greater than the differences between the GM lines. This was further confirmed by direct comparison of some of the GM lines with two non-GM genotypes; there was no separation among the GM lines and their control, but the two non-GM genotypes separated very clearly from each other and from all Desirée-based lines. In other words, there were considerably fewer differences between the GM and non-GM lines of the same genetic background than between different non-GM cultivars. Many of the proteins that contributed to the separation of the non-GM genotypes appeared to be involved in disease and defense responses, sugar and energy metabolism, or protein targeting and storage, and are presently considered to convey no safety risk.
Our results have been corroborated recently by Catchpole et al., who compared several GM potato lines and cultivars using metabolic profiling. The authors found differences between the GM lines only in those metabolites that were targets of the genetic modification; apart from those compounds, the GM lines could not be distinguished from their controls. On the other hand, all cultivars could be clearly distinguished from one another.
The results of both profiling studies are not surprising, considering what is now known about the nature of plant genome and its dynamics. Even though genetic modification does not generate major changes apart from the ones targeted, a protein identified at an increased level in the GM line compared to the conventional counterpart might be worth further attention if the level clearly falls outside the normal variation. This is to exclude any risks from, for example, potent allergens. As current profiling methods produce a huge amount of data, it is almost inevitable that some statistically significant differences will be found. Therefore the focus should be in truly consistent differences.
How feasible are profiling techniques in general as tools to provide additional data for the risk assessment of GM crops? Do they provide added value worth the investment? Do they give reassurance that unintended adverse effects have not occurred? Non-targeted methods, such as transcriptional, protein, and metabolite profiling, offer potentially unbiased approaches to the detection of unintended effects. Of these, transcriptomics is possibly the most comprehensive, with full genome arrays currently available for a limited number of plant species.
While it is clear that a comprehensive coverage of all proteins and metabolites present in a given tissue is difficult to obtain with current technologies, proteins are the key molecules of interest, as they are potential allergens and catalyse the synthesis of metabolites, some of which are potential toxins.
To assess observed differences within the context of natural variation in composition, comparative data of ‘normal’ protein levels are needed to understand the effect of genetic background, developmental stages, physiological states, environmental conditions, and cultivation techniques, and to be able to set the criteria against which a determination of a significant difference worth considering as a possible safety risk can be made. Currently there is very little information publicly available on protein patterns in potato tubers or in any other crops.
As with other profiling methods, proteomic screening is not yet routine for assessing the safety of GM products. However, proteomic profiling has the potential to reduce uncertainty by providing much more information about crop composition than does targeted analysis alone, especially in combination with other profiling methods. In addition, multivariate statistical methods can give a much better overall picture of how the given samples relate to each other than does the comparison of single compounds. These facts may make proteomics increasingly important when developing second generation GM crops with multiple genes, engineered metabolic pathways, or edible pharmaceuticals.
References:
Kuiper HA, Kleter GA, Noteborn HPJM & Kok EJ (2001) Assessment of the food safety issues related to genetically modified foods. Plant J 27, 503-528
Cellini F et al. (2004) Unintended effects and their detection in genetically modified crops. Food Chem Toxicol 42, 1089-1125
Lehesranta SJ, Davies HV, Shepherd LVT, Nunan N, McNicol JW, Auriola S, Koistinen KM, Suomalainen S, Kokko HI, & Kärenlampi SO (2005) Comparison of tuber proteomes of potato (Solanum sp.) varieties, landraces and genetically modified lines. Plant Physiol 138, 1690-1699
Catchpole GS, Beckmann M, Enot DP, Mondhe M, Zywicki B, Taylor J, Hardy N, Smith A, King RD, Kell DB, Fiehn O & Draper J (2005) Hierarchical metabolomics demonstrates substantial compositional similarity between genetically modified and conventional potato crops. Proc Natl Acad Sci USA 102, 14458-14462
Sirpa O. Kärenlampi and Satu J. Lehesranta
Institute of Applied Biotechnology, University of Kuopio
FIN-70211 Kuopio, Finland
skarenla@messi.uku.fi
Posted under Europe, Press Releases, Proteomics | No Comments
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory